P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY

• Paolo Ghia,
• John Allan,
• Tanya Siddiqi,
• William G. Wierda,
• Constantine Tam,
• Carol Moreno,
• Alessandra Tedeschi,
• Edith Szafer-Glusman,
• Cathy Zhou,
• Chris Abbazio,
• Jim Dean,
• Anita Szoke,
• Paul M. Barr

Affiliations

Paolo Ghia

1 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

John Allan

2 Weill Cornell Medicine, New York, NY, United States

Tanya Siddiqi

3 City of Hope National Medical Center, Duarte, CA, United States

William G. Wierda

4 Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States

Constantine Tam

5 Alfred Health and Monash University, Melbourne, VIC, Australia

Carol Moreno

6 Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Alessandra Tedeschi

7 ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

Edith Szafer-Glusman

8 AbbVie, South San Francisco, CA, United States

Cathy Zhou

8 AbbVie, South San Francisco, CA, United States

Chris Abbazio

8 AbbVie, South San Francisco, CA, United States

Jim Dean

8 AbbVie, South San Francisco, CA, United States

Anita Szoke

8 AbbVie, South San Francisco, CA, United States

Paul M. Barr

9 Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States